Background The present study aimed (i) to evaluate whether ceftriaxone treatment could affect not only intestinal oxalate-degrading bacteria number but their total activity to degrade oxalate and in uence oxalate homeostasis in rats, (ii) to test the effect of commercially available probiotics and a synbiotic on total fecal oxalate-degrading activity, (iii) and to estimate the ability of synbiotic to restore fecal oxalatedegrading activity and ceftriaxone-induced disruption of oxalate homeostasis in rats.Methods Twenty-eight female Wistar rats (200-300 g) were randomly divided into 4 groups (n = 7). Group 1 was treated with vehicle sterile water (0.1 ml, i.m., 14 days); Group 2 received synbiotic (30 mg/kg, per os, 14 days); Group 3 was treated with ceftriaxone (300 mg/kg, i.m., 7 days); Group 4 was supplemented with ceftriaxone and synbiotic. Oxalate-degrading bacteria number and their total activity, urinary and plasma oxalate concentrations were measured on days 1 and 57 after the treatment withdrawal.Results Ceftriaxone treatment reduced total fecal oxalate-degrading activity independently on oxalatedegrading bacteria number and increased urinary and plasma oxalate concentrations. The synbiotic had a high oxalate-degrading activity vs probiotics and was able to restore fecal oxalate-degrading activity and signi cantly decrease urinary oxalate excretion in antibiotic-treated rats.Conclusion Total fecal oxalate-degrading activity but not oxalate-degrading bacteria number should be thoroughly examined in the future to develop predictive diagnostics methods, targeted prevention and personalized treatment in kidney stone disease. Synbiotic supplementation had a bene cial effect on the total oxalate-degrading activity of gut microbiota, which resulted in decreased UOx excretion in rats.
Background The present study aimed (i) to evaluate whether ceftriaxone treatment could affect not only intestinal oxalate-degrading bacteria number but their total activity to degrade oxalate and influence oxalate homeostasis in rats, (ii) to test the effect of commercially available probiotics and a synbiotic on total fecal oxalate-degrading activity, (iii) and to estimate the ability of synbiotic to restore fecal oxalate-degrading activity and ceftriaxone-induced disruption of oxalate homeostasis in rats. Methods Twenty-eight female Wistar rats (200-300 g) were randomly divided into 4 groups (n = 7). Group 1 was treated with vehicle sterile water (0.1 ml, i.m., 14 days); Group 2 received synbiotic (30 mg/kg, per os, 14 days); Group 3 was treated with ceftriaxone (300 mg/kg, i.m., 7 days); Group 4 was supplemented with ceftriaxone and synbiotic. Oxalate-degrading bacteria number and their total activity, urinary and plasma oxalate concentrations were measured on days 1 and 57 after the treatment withdrawal. Results Ceftriaxone treatment reduced total fecal oxalate-degrading activity independently on oxalate-degrading bacteria number and increased urinary and plasma oxalate concentrations. The synbiotic had a high oxalate-degrading activity vs probiotics and was able to restore fecal oxalate-degrading activity and significantly decrease urinary oxalate excretion in antibiotic-treated rats. Conclusion Total fecal oxalate-degrading activity but not oxalate-degrading bacteria number should be thoroughly examined in the future to develop predictive diagnostics methods, targeted prevention and personalized treatment in kidney stone disease. Synbiotic supplementation had a beneficial effect on the total oxalate-degrading activity of gut microbiota, which resulted in decreased UOx excretion in rats.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.